Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOGI trial of gradual bosutinib dose escalation in second-/third-line chronic-phase chronic myeloid leukemia
jRCTs071180012Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in chronic myelogenous leukemia (CML), sponsored by Pfizer. Primary endpoint: Treatment discontinuation rate due to adverse events at 12 months. Started Feb 2019; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCTs071180012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180012.